|
Status |
Public on Oct 07, 2009 |
Title |
LOX1 Untreated 24hr 282295913 |
Sample type |
RNA |
|
|
Source name |
LOX1_Untreated_24hr
|
Organism |
Homo sapiens |
Characteristics |
Extract:LOX-1:213503 Extract Description:LOX1_Untreated_24hr:213503 Quality: Classification:Bad Quality: Gradient Severity:0.04 Quality: Distortion Severity:0.08 Quality: Defective Area (%):0.03 Quality: Outlier Area (%):0.02 Quality: 3'/5' Mean:1.74 Quality: Background Mean Dev.:2.24 Quality: Absent (%):61.27 Quality: Absent (%) Dev.:2.34 Quality: Scaling Factor:1.66 Quality: Scaling Factor Dev.:9.07 Pretreatment [C]:LOX1 Time point [C]:24 hours Treatment [C]:(Not applicable) Genomic ID [C]:213503 Cell name [C]:HAECT Treatment amount [C]:(Not applicable) Cell type [C]:Endothelial Organism species [C]:Human:Homo sapiens Cohort name [C]:LOX1_Untreated_24hr RNA extraction source key [A]:282295913
|
Extracted molecule |
polyA RNA |
Extraction protocol |
RNA was extracted from HAECT cells
|
Label |
biotin
|
Label protocol |
Affymetrix in-vitro labeling protocol
|
|
|
Hybridization protocol |
Affymetrix standard hybridization protocol
|
Scan protocol |
Affymetrix standard scan protocol
|
Description |
LOX1_Untreated_24hr:213503
|
Data processing |
Affymetrix MAS 5.0 algorithm
|
|
|
Submission date |
Oct 09, 2008 |
Last update date |
Oct 07, 2009 |
Contact name |
Andrew Hill |
E-mail(s) |
andrew.hill@pfizer.com
|
Phone |
617-674-6341
|
Organization name |
Pfizer
|
Department |
Research Business Technology
|
Street address |
300 Technology Square
|
City |
Cambridge |
State/province |
MA |
ZIP/Postal code |
02139 |
Country |
USA |
|
|
Platform ID |
GPL570 |
Series (1) |
GSE13139 |
LOX-1-dependent transcriptional regulation after oxidized LDL (OxLDL) treatment of human aortic endothelial cells. |
|